From Tissue to Answer: Integrated Solutions for Tissue and Molecular Pathology, from multiplex immunofluorescence to sample-to-result sequencing, powered by AI
STOCKHOLM, Sept. 15, 2026 /PRNewswire/ -- MGI Tech Co., Ltd. (MGI), a company committed to developing core tools and technologies that drive innovation in life science, today announced the European launch of VisiOmics (PMIF-20RS)*, a fully automated multiplex immunofluorescence (mIF) staining and imaging system, at the 38th European Congress of Pathology (ECP 2026), held in Stockholm from 12 to 16 September 2026.
Under the theme "From Tissue to Answer", the launch anchors a comprehensive pathology portfolio spanning tissue and molecular pathology. Whether the question is asked of proteins in a tissue section or of nucleic acids in a sample, MGI's platforms deliver an accurate answer with AI embedded at every step.
VisiOmics: is now commercially available in Europe
VisiOmics is a fully automated mIF staining and imaging system that brings high-plex, automated tissue analysis within reach of routine laboratory workflows. VisiOmics enables multiplex detection of protein markers within a single tissue section, allowing researchers to characterize cell populations and investigate their spatial organization within the tissue microenvironment:
"To gain deeper insights into disease biology, pathology research is increasingly combining morphological assessment with multiplex spatial proteomics," said Fang Chen, Vice President of MGI and General Manager of Europe & Africa at MGI. "With VisiOmics now available in Europe, alongside PrepALL and AIO for molecular pathology, we are offering a complete 'From Tissue to Answer' portfolio, whether the starting point is proteins in tissue or nucleic acids in a sample."
MGI is also partnering with the Fraunhofer Institute for Integrated Circuits IIS to demonstrate the compatibility of multiplex immunofluorescence images generated by VisiOmics with MIKAIA®, Fraunhofer IIS's image analysis software for digital pathology and spatial biology research. The collaboration aims to show how researchers can use VisiOmics image data within MIKAIA workflows for cell segmentation, phenotyping and spatial analysis. This work supports greater flexibility in downstream analysis, helping laboratories connect automated tissue imaging with tools suited to their research questions.
Also on display: Customisable High-Throughput Multiplex Tissue Imaging
AI-based pathology research depends on well-characterised tissue image datasets. To support their generation at scale, MGI is also presenting Path-P96 WF, a customisable platform for automated multiplex immunofluorescence staining and imaging using standard pathology slides. The system processes up to 32 slides per batch, supports continuous loading and walk-away operation, and enables detection of more than 100 protein markers through cyclic staining.
Designed to accommodate different research workflows, Path-P96 WF can be configured for applications in drug discovery and spatial biology, including target validation, spatial phenotyping and image dataset generation for AI-based pathology research.
Molecular pathology: From Library Prep to Integrated Reporting
MGI now offers PrepLPS(PrepALL Library Prep Edition), a compact liquid-handling platform for NGS library preparation with eight independent channels (0.5–1,200 µL), AI-based machine vision and ready-to-run workflows. Early Access is now open for European laboratories.
AIO (All-in-one) condenses the entire workflow — library preparation, sequencing and reporting — into a single sample-to-result platform: nucleic acid in, report out, in about 11 hours with roughly 10 minutes of hands-on time. AIO is demonstrated live at the booth, and the platform is open for OEM partnerships in Europe.
AI Across the Portfolio: From Analysis to Intelligent Lab Agents
Across the portfolio, AI is built in, not bolted on. Backed by Genoria AI, each platform ships with AI-powered image analysis (FluoXpert Vision on PMIF-20RS), natural-language workflow orchestration on Path-P96 WF, machine-vision monitoring on PrepALL, and intelligent library-pooling strategies on AIO.
About MGI
Founded in 2016, MGI Tech Co., Ltd. (or its subsidiaries, together referred to as MGI, stock code:688114.SH) is committed to building core tools and technologies that drive innovation in life science. As one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers, MGI empowers global users with scalable sequencing capabilities ranging from Gb to Tb levels. MGI also stands out as the only provider of a full-stack product portfolio that spans three core segments: SEQ ALL (short- and long-read sequencing), GLI (Generative Lab Intelligence), and Multi-Omics.
To learn more, please visit MGI Tech, LinkedIn, X, Instagram, and YouTube.
About Fraunhofer IIS
As the largest Fraunhofer Institute, Fraunhofer Institute for Integrated Circuits IIS, headquartered in Erlangen, is a global leader in applied research, driving innovation for transformative products and services that shape the digital future.
Across seven research divisions, the institute develops pioneering solutions that advance technological progress, enhance economic competitiveness, and promote a sustainable society. Its strong performance is built on four core areas of expertise: artificial intelligence, microelectronics, data acquisition and analysis, and signal processing and data transmission. These competencies are combined strategically to meet the specific needs of its clients.
About Genoria AI
Genoria AI, a subsidiary of MGI Tech, is an AI4S company building self-evolving labs to scale agentic discovery. Learn more at genoria.ai/en
*for research use only
View original content:https://www.prnewswire.co.uk/news-releases/mgi-tech-launches-visiomics-in-europe-and-unveils-ai-enabled-pathology-portfolio-at-ecp-2026-302878642.html
